Updated on 7 October 2014
The probiotic has demonstrated an exceptional safety record, obtaining a FDA GRAS status from the United States FDA
Singapore: Ganeden Biotech revealed that its patented probiotic ingredient Ganeden BC30 (Bacillus coagulans GBI-30, 6086) has received approval from the Food and Drug Administration for sale in four significant Asian markets: Japan, India, Taiwan and the Philippines.
The probiotic will be made available as a result of Ganeden's established partnerships- with Maypro Industries in Japan and Connell Bros in India, Taiwan and the Philippines. Ganeden BC30 is a spore-former and remains viable through most manufacturing processes and survives the low pH of stomach acid.
Mr Stephen Quinn, international business development and regulatory manager of Ganeden Biotech, said, "Consumers in these Asian markets are already familiar with the benefits of probiotics. The regulatory approvals provide a great deal of opportunity for probiotic innovation within these thriving functional food and beverage markets, and we are thrilled to be able to introduce the unique formulating capabilities of Ganeden BC30."
He added that safety and efficacy of the probiotic ingredient was established by 19 published studies and it had demonstrated an exceptional safety record, obtaining a FDA GRAS status from the United States FDA.